Quince Therapeutics appoints Rajiv Patni as Class III director

Quince Therapeutics, Inc.

Rajiv Patni appointed to board effective Feb 15, 2024 as Class III director, term through 2025 annual meeting.
Receives $38,000 annual retainer plus 54,000-share stock option grant under 2019 Equity Incentive Plan.
Options vest in equal annual installments over 3 years, exercise price equals Feb 15 closing price.
Entered standard indemnification agreement; no family relationships or related party transactions with company.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Rajiv Patni

director

QNCX · Quince Therapeutics, Inc.

Effective: 2024-02-15
Filed: February 15, 2024, 6:59 PM ET

the board of directors (the “ Board ”) of Quince Therapeutics, Inc. (the “ Company ”) appointed Rajiv Patni to serve as a director of the Company, effective as of February 15, 2024.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Rajiv Patni was appointed as director at Quince Therapeutics, Inc..

Action: appointed
Role: director

Exact text from the filing

the board of directors (the “ Board ”) of Quince Therapeutics, Inc. (the “ Company ”) appointed Rajiv Patni to serve as a director of the Company, effective as of February 15, 2024.

View on SEC.gov

Quince Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-24-037521

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.